Unfavorable efficacy to (131)I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb

The BRAFV600E mutation has shown a close relationship of aggressiveness in papillary thyroid carcinoma (PTC), while it remains unclear about its influence on the therapeutic response. As a common clinicopathologic risk factor, thyroglobulin antibody (TgAb) may have a correlation of prognosis in PTC....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Na, Liang, Jun, Lin, Yan-Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722572/
https://www.ncbi.nlm.nih.gov/pubmed/29228620
http://dx.doi.org/10.18632/oncotarget.22129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722572/
https://www.ncbi.nlm.nih.gov/pubmed/29228620
http://dx.doi.org/10.18632/oncotarget.22129

Ejemplares similares